Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Exicure Inc (XCUR)

Exicure Inc (XCUR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,667
  • Shares Outstanding, K 8,648
  • Annual Sales, $ 28,830 K
  • Annual Income, $ -2,580 K
  • 60-Month Beta 1.31
  • Price/Sales 0.14
  • Price/Cash Flow N/A
  • Price/Book 0.52
Trade XCUR with:
  • Price/Earnings ttm 0.33
  • Earnings Per Share ttm 0.70
  • Most Recent Earnings $-0.68 on 08/11/23
  • Latest Earnings Date 04/01/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5000 +7.94%
on 04/04/24
0.7280 -25.87%
on 04/16/24
-0.0889 (-14.14%)
since 03/22/24
3-Month
0.5000 +7.94%
on 04/04/24
0.7930 -31.94%
on 03/05/24
-0.0213 (-3.80%)
since 01/22/24
52-Week
0.3647 +47.98%
on 12/07/23
1.5000 -64.02%
on 06/30/23
-0.4504 (-45.49%)
since 04/21/23

Most Recent Stories

More News
Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that it...

XCUR : 0.5397 (-3.80%)
Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that,...

XCUR : 0.5397 (-3.80%)
Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update

Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today reported financial...

XCUR : 0.5397 (-3.80%)
Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors

Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced the closing...

XCUR : 0.5397 (-3.80%)
Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements

Exicure, Inc. (NASDAQ: XCUR) an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced the termination...

XCUR : 0.5397 (-3.80%)
Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today reported financial...

XCUR : 0.5397 (-3.80%)
Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives

Exicure, Inc. (NASDAQ: XCUR) today announced plans to restructure the Company and align resources to continue exploring strategic alternatives that maximize stockholder value. After a strategic review...

XCUR : 0.5397 (-3.80%)
Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference

Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological...

XCUR : 0.5397 (-3.80%)
Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress

Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological...

XCUR : 0.5397 (-3.80%)
Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological...

XCUR : 0.5397 (-3.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Exicure Inc. is a clinical-stage biotechnology company. It is engaged in developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid technology. Exicure Inc. is based in IL, United States.

See More

Key Turning Points

3rd Resistance Point 0.5998
2nd Resistance Point 0.5859
1st Resistance Point 0.5628
Last Price 0.5397
1st Support Level 0.5258
2nd Support Level 0.5119
3rd Support Level 0.4888

See More

52-Week High 1.5000
Fibonacci 61.8% 1.0663
Fibonacci 50% 0.9323
Fibonacci 38.2% 0.7984
Last Price 0.5397
52-Week Low 0.3647

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar